multipl
sclerosi
ms
character
inflammatori
lesion
predominantli
white
matter
region
brain
earli
diseas
longterm
progress
gray
matter
atrophi
detect
mri
imag
mark
neurodegen
phase
diseas
reactiv
gliosi
demyelin
axon
damag
white
matter
attribut
cnsinfiltr
immun
cell
none
treatment
current
use
ms
revers
directli
prevent
neurodegener
cn
instead
reduc
inflamm
attenu
cell
activ
andor
infiltr
cn
cure
ms
patient
use
current
treatment
continu
experi
diseas
progress
discoveri
drug
prevent
demyelin
neuron
loss
critic
import
howev
differenti
effect
immun
cell
cn
difficult
experiment
outcom
ie
reduc
damag
cn
look
regardless
mechan
occur
therefor
assess
cn
protect
must
partner
assess
cnsinfiltr
immun
cell
prolifer
immun
cell
peripheri
determin
pharmacolog
agent
affect
diseas
mechan
experiment
autoimmun
encephalomyel
eae
wellestablish
anim
model
autoimmun
inflammatori
disord
directli
respons
discoveri
drug
current
use
treat
ms
mice
often
use
eae
mice
popular
strain
base
avail
genet
variant
mice
induc
eae
exhibit
chronic
diseas
progress
onset
around
day
postinduct
infiltr
spinal
cord
parenchyma
cerebellum
characterist
histopatholog
anim
absenc
infiltr
cortic
parenchyma
addit
cortic
lesion
demyelin
brain
hallmark
diseas
rel
absent
mice
therefor
may
prefer
possibl
use
sjl
mice
relapsingremit
diseas
lesion
found
brain
spinal
cord
appear
similar
ms
treatment
classifi
neuroprotect
immun
cell
never
reach
cn
therefor
protocol
make
use
flow
cytometr
analysi
brain
spinal
cord
spleen
eae
mice
determin
effect
treatment
immun
cell
infiltr
cn
prolifer
immun
cell
peripheri
previous
demonstr
immunohistochem
analys
cn
tissu
determin
extent
natur
neuroprotect
also
describ
combin
method
allow
determin
whether
immun
cell
activ
prolifer
peripheri
whether
immun
cell
enter
cn
whether
cn
protect
inflamm
damag
neuroprotect
effect
suspect
despit
effect
immun
system
experiment
alter
treatment
start
time
immun
cell
infiltr
cn
occur
present
protocol
use
two
differ
model
activ
eae
cellmedi
anim
model
ms
flow
cytometri
analysi
combin
immunohistochemistri
variou
timepoint
diseas
determin
efficaci
experiment
therapi
differ
aspect
ms
pathogenesi
method
assist
research
differenti
effect
immun
cell
prolifer
infiltr
versu
cn
protect
make
easier
narrow
drug
act
diseas
pathogenesi
use
two
model
eae
understand
pharmacolog
agent
provid
cn
protect
either
attenu
cnsinfiltr
cell
prevent
myelin
axon
injuri
onslaught
inflammatori
immun
cell
infiltr
determin
therapeut
agent
prevent
immun
cell
infiltr
spinal
cord
mous
model
chronic
eae
use
immun
cell
infiltr
diseas
patholog
predominantli
locat
spinal
cord
figur
determin
therapeut
drug
provid
cn
protect
intrus
immun
cell
cn
sjl
anim
model
relapsingremit
eae
use
demonstr
diseas
patholog
brain
spinal
cord
figur
clinic
assess
relev
clinic
assess
made
accord
follow
rubric
typic
figur
atyp
figur
eae
typic
clinic
diseas
score
abnorm
behavior
pick
base
tail
tail
may
rotat
quickli
much
like
helicopt
rotor
hind
leg
spread
apart
clinic
score
partial
limp
tail
may
determin
lift
mous
base
tail
normal
helicopterlik
rotat
may
weaken
absent
part
tail
may
complet
limp
help
way
determin
extent
tail
paralysi
run
one
finger
length
tail
unparalyz
tail
usual
curl
around
finger
partial
paralyz
tail
unabl
clinic
score
repres
complet
paralyz
tail
movement
tail
occur
pick
mous
base
tail
clinic
score
repres
partial
hind
limb
paralysi
determin
score
requir
mous
free
move
flat
surfac
one
hind
limb
drag
mous
move
forward
one
hind
limb
appear
partial
paralyz
score
may
given
clinic
score
repres
complet
hind
limb
paralysi
score
mous
unabl
move
hind
limb
drag
forward
use
front
limb
clinic
score
repres
moribund
mous
mous
difficulti
move
across
cage
breath
mous
drag
along
bottom
cage
breath
labor
mous
human
euthan
clinic
score
repres
mous
found
dead
cage
score
unusu
caus
death
eae
investig
atyp
clinic
diseas
may
may
accompani
paralysi
may
necessari
includ
two
separ
score
system
mous
present
atyp
diseas
plu
typic
symptom
score
abnorm
behavior
typic
score
system
clinic
score
repres
slight
head
turn
tilt
mous
walk
may
determin
allow
mous
walk
forward
observ
constant
left
right
direction
movement
clinic
score
repres
pronounc
head
turn
poor
right
abil
atyp
score
mous
direction
movement
may
slight
difficulti
balanc
clinic
score
repres
inabl
walk
straight
line
mous
difficulti
balanc
may
use
side
cage
help
right
walk
clinic
score
repres
mous
lay
side
unabl
walk
due
balanc
issu
mous
may
abl
drag
along
bottom
cage
may
direction
movement
clinic
score
repres
continu
roll
unless
support
mous
reach
score
human
euthan
clinic
score
repres
mous
found
dead
cage
score
unusu
caus
death
eae
investig
may
necessari
allow
inbetween
score
eg
ad
score
mous
condit
chang
slightli
choos
two
score
difficult
exampl
mous
begin
move
slowli
normal
counterpart
display
paralysi
mous
clasp
hind
feet
front
instead
splay
leg
pick
tail
may
given
score
mous
drag
along
bottom
cage
abl
twitch
hind
limb
period
touch
may
given
score
assess
reduct
immun
cell
infiltr
induct
eae
mous
model
figur
day
antigen
present
prolifer
cell
spleen
occur
day
follow
immun
cell
infiltr
cn
around
day
approxim
day
initi
immun
cell
infiltr
mice
present
clinic
score
assess
therapeut
agent
block
immun
cell
infiltr
spinal
cord
drug
vehicl
introduc
day
antigen
present
prolifer
spleen
immun
cell
start
infiltr
spinal
cord
immun
cell
infiltr
attenu
clinic
diseas
cours
reflect
improv
clinic
score
rise
phase
diseas
day
figur
reduct
immun
cell
infiltr
would
also
result
diminish
neuroinflamm
reactiv
astrocytosi
microgliosi
consid
major
hallmark
neuroinflamm
stain
astrocyt
gfap
microglia
use
assess
chang
mean
area
fraction
stain
quantifi
neuroinflamm
figur
determin
immun
cell
infiltr
reduc
spinal
cord
remov
process
flow
cytometri
analysi
peak
diseas
figur
approxim
day
ensur
largest
number
immun
cell
enter
spinal
cord
entranc
cell
cn
consid
initi
inflammatori
event
cell
found
anim
model
eae
well
ms
patient
taken
togeth
flow
cytometr
analysi
includ
assess
type
pathogen
cell
furthermor
treg
wellcharacter
suppressor
cell
dampen
diseas
therefor
percentag
treg
total
popul
must
evalu
compar
percentag
effector
cell
popul
reveal
overal
reduct
cell
infiltr
occur
skew
cell
phenotyp
cn
repres
dot
plot
figur
demonstr
reduct
overal
number
infiltr
cell
spinal
cord
drugtreat
mice
compar
spinal
cord
vehicletr
mice
number
upper
right
quadrant
evalu
treg
cell
follow
signatur
protein
evalu
respect
reduc
figur
statist
analysi
perform
cell
number
demonstr
signific
reduct
figur
rule
skew
cell
subset
statist
evalu
proport
cell
perform
figur
elimin
possibl
reduct
cnsinfiltr
cell
consequ
inhibit
prolifer
activ
differenti
peripheri
number
activ
prolifer
cell
addit
proport
cell
subtyp
need
evalu
chang
percentag
found
activ
differenti
unaffect
figur
furthermor
chang
cell
found
prolifer
unaffect
figur
drug
treatment
introduc
day
later
avoid
alter
initi
antigen
present
cell
activ
peripheri
howev
genet
model
protein
often
delet
constitut
embryogenesi
induc
induct
eae
make
splenocyt
assess
high
import
assess
cn
protect
demonstr
particular
therapeut
agent
modul
diseas
patholog
cn
immun
cell
infiltr
drug
intervent
administ
first
peak
clinic
diseas
score
sjl
model
eae
advantag
experi
sinc
mice
exhibit
relapsingremit
phenotyp
drug
treatment
prevent
myelinaxon
degener
improv
clinic
score
observ
figur
patholog
assess
myelin
must
corrobor
reduct
myelin
damag
consist
improv
clinic
score
quantit
evalu
myelin
integr
dab
stain
myelin
basic
protein
mbp
perform
follow
statist
analysi
optic
densiti
stain
figur
substanti
neuroinflamm
sustain
decreas
therapeut
intervent
reactiv
gliosi
assess
measur
mean
fraction
area
reactiv
gliosi
describ
figur
corrobor
therapeut
intervent
directli
protect
cn
without
immunomodulatori
effect
attenu
immun
cell
infiltr
cn
prolifer
spleen
must
discount
address
method
brain
spinal
cord
assess
immun
cell
infiltr
assess
peripher
cell
prolifer
activ
perform
describ
figur
taken
togeth
therapeut
agent
block
cell
injuri
cn
evid
reduct
cnsinfiltr
cell
prolifer
cell
peripheri
cnsprotect
treatment
figur
repres
result
clinic
score
eae
sjl
mice
clinic
score
mean
sem
mice
n
induc
produc
eae
chronic
diseas
b
clinic
score
mean
sem
sjl
mice
n
induc
produc
eae
relapsingremit
diseas
c
clinic
score
rubric
use
track
typic
diseas
progress
eae
mice
clinic
score
rubric
use
track
atyp
diseas
progress
eae
mice
pleas
click
view
larger
version
figur
figur
pharmacolog
treatment
prior
immun
cell
infiltr
mice
eae
clinic
score
mean
sem
mice
treat
pb
n
sa
n
day
postimmun
data
three
pool
independ
experi
statist
differ
determin
use
nonparametr
twotail
mannwhitney
u
test
p
reprint
permiss
figur
immunofluoresc
stain
quantif
reactiv
gliosi
spinal
cord
control
eae
treat
mice
fluoresc
label
gfap
astrocyt
microglia
spinal
cord
control
unimmun
mice
left
panel
eae
mice
treat
pb
middl
panel
sa
right
panel
scale
bar
quantif
stain
determin
use
area
fraction
techniqu
measur
percent
immunoposit
area
gfap
b
c
mean
sem
n
control
n
sastreat
n
pbstreat
mice
section
per
mous
statist
differ
determin
use
oneway
anova
p
p
p
reprint
permiss
pleas
click
view
larger
version
figur
figur
fac
analysi
eae
mous
spinal
cord
demonstr
reduc
cell
infiltr
treat
mice
mice
treat
sa
pb
begin
postinduct
eae
spinal
cord
obtain
day
repres
dot
plot
show
cell
gate
upper
panel
regulatori
cell
lower
panel
dot
plot
show
percentag
upper
right
quadrant
b
absolut
number
cell
well
cell
statist
analyz
c
chang
percentag
cell
popul
sa
pbstreat
eae
mice
also
examin
mean
sem
n
pb
treat
n
sa
treat
two
independ
experi
twotail
test
use
bar
graph
p
reprint
permiss
pleas
click
view
larger
version
figur
figur
fac
analysi
eae
mous
spleen
demonstr
equival
cell
express
profil
prolifer
treat
untreat
mice
spleen
pb
sastreat
mice
analyz
postinduct
eae
percentag
cell
regulatori
cell
spleen
pbstreat
n
sastreat
n
mice
two
independ
experi
b
left
panel
percentag
cell
popul
naiv
spleen
n
well
pb
n
sastreat
mice
n
induc
eae
oneway
anova
test
demonstr
statist
signific
proport
cell
naiv
spleen
compar
either
pb
sastreat
eae
spleen
signific
observ
pb
sastreat
eae
spleen
b
right
panel
repres
dot
plot
number
indic
proport
prolifer
dot
plot
show
percentag
bar
graph
repres
twotail
test
p
reprint
permiss
pleas
click
view
larger
version
figur
figur
pharmacolog
treatment
immun
cell
infiltr
sjl
mice
eae
clinic
score
mean
sem
sjl
mice
treat
pb
n
sa
n
day
postimmun
dash
line
data
mean
sem
clinic
score
statist
differ
determin
use
nonparametr
twotail
mannwhitney
u
test
p
top
line
repres
valu
use
statist
analysi
reprint
permiss
figur
quantif
mbp
stain
use
optic
densiti
repres
stain
mbp
thorac
spinal
cord
unspecifi
genet
knockout
mous
compar
litterm
control
mous
induc
eae
bracket
indic
repres
area
reduc
mbp
stain
indic
demyelin
b
mbp
stain
thorac
spinal
cord
unspecifi
genet
knockout
mous
c
unspecifi
genet
knockout
mice
induc
eae
ko
n
mice
lumbar
thorac
section
per
anim
exhibit
higher
optic
densiti
od
mbp
stain
spinal
cord
wildtyp
wt
n
mice
lumbar
thorac
section
per
anim
mice
induc
eae
statist
analyz
use
twotail
test
p
error
bar
repres
sem
scale
bar
patient
ms
continu
experi
diseas
relaps
take
drug
attenu
cell
activ
andor
infiltr
cn
warrant
develop
treatment
option
directli
protect
cn
eae
classic
use
model
symptom
ms
power
tool
studi
natur
interact
immun
system
cn
vivo
use
time
treatment
consider
eae
eg
initi
diseas
conjunct
examin
immun
cell
infiltr
cn
prolifer
activ
peripheri
possibl
delin
effect
treatment
immun
system
cn
eae
mous
wide
util
eae
sjl
mous
may
repres
major
ms
case
mice
relapsingremit
phenotyp
infiltr
immun
cell
parenchyma
brain
sjl
mice
clear
recoveri
remiss
well
make
possibl
begin
treatment
diseas
present
time
reduc
inflamm
import
consid
sjl
mice
alway
relaps
remit
synchroni
result
potenti
larg
variabl
result
pool
therefor
research
may
opt
show
repres
result
clinic
score
one
anim
take
mice
fac
analysi
histolog
individu
point
diseas
progress
consid
manipul
made
eae
mice
assist
determin
treatment
affect
immun
system
cn
mani
option
treatment
begin
connot
whether
immun
cell
enter
cn
may
interact
cn
treatment
onset
symptom
impli
immun
cell
yet
enter
caus
damag
cn
treatment
onset
symptom
impli
immun
cell
enter
cn
caus
damag
use
sjl
mice
treatment
also
begin
relaps
immun
cell
activ
infiltr
caus
inflamm
remiss
immun
cell
may
less
preval
cn
less
inflamm
initi
hypothes
regard
treatment
affect
cn
immun
system
made
consid
immun
cell
patholog
process
treatment
number
way
treatment
affect
immun
cell
cn
end
result
reduc
sever
eae
symptom
therefor
necessari
use
flow
cytometr
analysi
immunohistochemistri
look
immun
cell
affect
peripheri
cn
whether
immun
cell
enter
cn
cn
react
treatment
flow
cytometr
analysi
spinal
cord
determin
mani
cell
enter
cn
given
time
one
determin
effect
due
reduc
immun
cell
traffick
unless
prolifer
immun
cell
unaffect
spleen
therefor
necessari
analyz
peripher
cn
tissu
determin
result
mean
mechanist
tissu
compar
also
possibl
immun
cell
activ
profil
alter
treatment
exampl
switch
pathogen
helper
cellheavi
profil
regulatori
cellheavi
profil
look
marker
differ
cell
type
compar
percent
express
treat
untreat
anim
therefor
also
import
consider
emerg
concept
ms
research
suggest
b
cell
play
import
role
autoimmun
demyelin
base
studi
show
b
cell
necessari
reactiv
cell
concept
support
success
treatment
rituximab
antibodi
express
surfac
b
cell
demonstr
success
monoclon
antibodi
ocrelizumab
clinic
trial
drug
target
differ
epitop
may
improv
efficaci
b
celltarget
therapeut
one
limit
techniqu
present
possibl
immun
cell
enter
cn
unabl
travel
parenchyma
immunohistochemistri
use
detect
perivascular
cuf
immun
cell
evalu
distanc
travel
parenchyma
treat
untreat
anim
anoth
potenti
limit
involv
effect
microbiom
eae
pathogenesi
commens
gut
microbiota
heavili
influenc
diseas
pathogenesi
therefor
mice
hous
differ
coloni
even
differ
cage
vast
differ
diseas
sever
accordingli
alway
prefer
possibl
use
litterm
control
rais
cage
experi
involv
eae
final
note
experiment
desir
elimin
effect
immun
cell
prolif
chang
peripheri
may
possibl
use
passiv
transfer
induct
rather
activ
induct
describ
protocol
confirm
neuroprotect
accomplish
use
cocultur
system
test
specif
mechan
cell
death
use
condit
knockout
mice
allow
delet
protein
select
cell
type
furthermor
extend
explor
pharmacolog
agent
neuroprotect
marker
axon
transect
neuron
death
includ
anoth
area
import
remyelin
injur
axon
unabl
remyelin
lend
support
neuroprotect
therapi
import
part
remyelin
therapi
addit
unmyelin
axon
vulner
injuri
myelin
axon
suggest
axon
becom
demyelin
therapeut
intervent
promot
time
remyelin
prevent
axon
injuri
explor
avenu
vivo
model
demyelin
remyelin
may
use
ie
cuprizon
lysolecithin
method
describ
herein
focus
assess
neuroprotect
quantifi
myelin
loss
evalu
remyelin
number
progenitor
cell
well
abil
prolifer
matur
would
also
import
investig
mention
altern
model
one
must
also
consid
differ
model
enceph
viral
mediat
two
wellcharacter
rna
viral
model
produc
myelin
loss
one
theiler
murin
encephalomyel
nonenvelop
picornavirida
viru
mous
hepat
viru
member
coronavirida
viru
famili
eae
valuabl
tool
studi
manipul
treatment
affect
immun
system
cn
vivo
protocol
describ
help
determin
treatment
affect
diseas
process
whether
peripheri
bloodbrain
barrier
cn
current
treatment
ms
cure
diseas
patient
often
experi
declin
time
similarli
diseas
involv
immun
cell
infiltr
cn
degrad
myelin
includ
acut
dissemin
encephalomyel
transvers
myeliti
neuromyel
optica
lack
treatment
protect
cn
directli
attack
infiltr
immun
cell
take
consider
time
treatment
use
flow
cytometr
analysi
spleen
spinal
cord
conjunct
immunohistochemistri
cn
assess
inflamm
damag
allow
mechanist
determin
made
regard
treatment
author
noth
disclos
